NEW YORK, May 1, 2013 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that trading of GW Pharmaceuticals (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its cannabinoid product platform, commenced on The NASDAQ Stock Market on May 1, 2013. GW is a biopharmaceutical company at the forefront of plant-derived cannabinoid therapeutics. In its 14 years of operations, the company has established a world leading position in the development of prescription cannabinoid medicines through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 20 countries outside of the United States. Sativex is also in Phase III clinical development for the treatment of cancer pain, the lead indication for the U.S. market and the company anticipates top-line results from the first of two Phase 3 trials will be available in mid-2014. GW has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively. "Through its product Sativex and broad pipeline, GW Pharmaceuticals has established itself as the world leader in cannabinoid science," said Nelson Griggs, Senior Vice President, NASDAQ OMX. "GW truly exemplifies the type of groundbreaking and innovative pharmaceutical company that partners with NASDAQ and we are proud to welcome them on our exchange." Since its inception, NASDAQ OMX has consistently been the exchange of choice for progressive and cutting-edge health care and pharmaceutical companies like GW Pharmaceuticals. NASDAQ is currently home to more than 420 healthcare companies representing 73 percent of all U.S. listed companies in the sector, including industry-leading pharmaceutical companies such as Amgen Inc, Gilead Sciences Inc., Celgene Corp. and Biogen Idec Inc.
About NASDAQ OMXThe inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook ( http://www.facebook.com/NASDAQ) and Twitter ( http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500) The information contained above is provided by The NASDAQ OMX Group, Inc. for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.